New therapeutic strategies for the treatment of male lower urinary tract symptoms

References

• AbramsPCardozoLFallMThe standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence SocietyUrology2003611374912559262
   PubMed Web of Science ®Google Scholar
• ChappleCRWeinAJAbramsPLower urinary tract symptoms revisited: a broader clinical perspectiveEur Urol200854356356918423969
   PubMed Web of Science ®Google Scholar
• ChappleCAbramsPLower Urinary Tract Symptoms (LUTS): An International Consultation on Male LUTSMontrealSociété Internationale d’Urologie2013
   Google Scholar
• MartinSAHarenMTMarshallVRLangeKWittertGAMembers of the Florey Adelaide Male Ageing StudyPrevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian menWorld J Urol201129217918420963421
   PubMed Web of Science ®Google Scholar
• KupelianVWeiJTO’LearyMPPrevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) SurveyArch Intern Med2006166212381238717130393
   PubMed Web of Science ®Google Scholar
• IrwinDEMilsomIHunskaarSPopulation-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC studyEur Urol200650613061314 discussion 1314–131517049716
   PubMed Web of Science ®Google Scholar
• FüllhaseCChappleCCornuJ-NSystematic review of combination drug therapy for non-neurogenic male lower urinary tract symptomsEur Urol201364222824323375241
   PubMed Web of Science ®Google Scholar
• AbramsPBenign prostatic hyperplasia: poorly correlated with symptomsBMJ199330768972017688255
   PubMed Web of Science ®Google Scholar
• DmochowskiRRStaskinDOveractive bladder in men: special considerations for evaluation and managementUrology2002605 Suppl 15662 discussion 62–6312493356
   PubMed Web of Science ®Google Scholar
• WassonJHRedaDJBruskewitzRCElinsonJKellerAMHendersonWGA comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the ProstateN Engl J Med1995332275797527493
   PubMed Web of Science ®Google Scholar
• FlaniganRCRedaDJWassonJHAndersonRJAbdellatifMBruskewitzRC5-Year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative studyJ Urol199816011216 discussion 16–179628595
   PubMed Web of Science ®Google Scholar
• RoosenAChappleCRDmochowskiRRA refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literatureEur Urol200956581081919683859
   PubMed Web of Science ®Google Scholar
• ChappleCRRoehrbornCGA shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladderEur Urol200649465165816530611
   PubMed Web of Science ®Google Scholar
• McConnellJDRoehrbornCGBautistaOMThe long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasiaN Engl J Med2003349252387239814681504
   PubMed Web of Science ®Google Scholar
• RoehrbornCGSiamiPBarkinJThe effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT studyEur Urol201057112313119825505
   PubMed Web of Science ®Google Scholar
• KortmannBBMFloratosDLKiemeneyLALMWijkstraHde la RosetteJJMCHUrodynamic effects of alpha-adrenoceptor blockers: a review of clinical trialsUrology20036211912837408
   PubMed Web of Science ®Google Scholar
• BarendrechtMMAbramsPSchumacherHde la RosetteJJMCHMichelMCDo alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?Neurourol Urodyn200827322623017638312
   PubMed Web of Science ®Google Scholar
• OelkeMBachmannADescazeaudAEAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstructionEur Urol201364111814023541338
   PubMed Web of Science ®Google Scholar
• NaslundMJMinerMA review of the clinical efficacy and safety of 5α-reductase inhibitors for the enlarged prostateClin Ther2007291172517379044
   PubMed Web of Science ®Google Scholar
• NickelJCFradetYBoakeRCEfficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year StudyCMAJ19961559125112598911291
   PubMed Web of Science ®Google Scholar
• RoehrbornCGBoylePNickelJCHoefnerKAndrioleGARIA3001 ARIA3002 and ARIA3003 Study InvestigatorsEfficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasiaUrology200260343444112350480
   PubMed Web of Science ®Google Scholar
• ChughtaiBEltermanDSLeeRTeAEKaplanSAExperience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasiaTher Adv Urol20124526727223024707
   PubMedGoogle Scholar
• SextonCCCoyneKSKoppZSThe overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTSBJU Int2009103Suppl 3122319302498
   PubMed Web of Science ®Google Scholar
• PetersTJDonovanJLKayHEThe International Continence Society “Benign Prostatic Hyperplasia” Study: the botherosomeness of urinary symptomsJ Urol199715738858899072592
   PubMed Web of Science ®Google Scholar
• DimitropoulosKGravasSSolifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasiaDrug Des Devel Ther2015917071716
   Web of Science ®Google Scholar
• KaplanSAWeinAJStaskinDRRoehrbornCGSteersWDUrinary retention and post-void residual urine in men: separating truth from traditionJ Urol20081801475418485378
   PubMed Web of Science ®Google Scholar
• KaplanSAWalmsleyKTeAETolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasiaJ Urol2005174622732275 discussion 2275–227616280803
   PubMed Web of Science ®Google Scholar
• YokoyamaTUematsuKWatanabeTNaftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled studyScand J Urol Nephrol200943430731419396723
   PubMed Web of Science ®Google Scholar
• YamaguchiOLatest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of actionInt J Urol2013201283923190275
   PubMed Web of Science ®Google Scholar
• VijMDrakeMJClinical use of the β3 adrenoceptor agonist mirabegron in patients with overactive bladder syndromeTher Adv Urol20157524124826425139
   PubMedGoogle Scholar
• KanaiAWyndaeleJ-JAnderssonK-EResearching bladder afferents-determining the effects of β(3) -adrenergic receptor agonists and botulinum toxin type-ANeurourol Urodyn201130568469121661014
   PubMed Web of Science ®Google Scholar
• SolerRAnderssonK-EChancellorMBFuture direction in pharmacotherapy for non-neurogenic male lower urinary tract symptomsEur Urol201364461062123711541
   PubMed Web of Science ®Google Scholar
• FüllhaseCSolerRGratzkeCNew strategies in treating male lower urinary tract symptomsCurr Opin Urol2014241293524285261
   PubMed Web of Science ®Google Scholar
• SchauerIMadersbacherSMedical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: anything new in 2015Curr Opin Urol201525161125393269
   PubMed Web of Science ®Google Scholar
• KhullarVAmarencoGAnguloJCEfficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trialEur Urol201363228329523182126
   PubMed Web of Science ®Google Scholar
• ChappleCRKaplanSAMitchesonDRandomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladderEur Urol201363229630523195283
   PubMed Web of Science ®Google Scholar
• EUROPEAN MEDICINES AGENCYSummary of product characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002388/WC500137309.pdfAccessed, March 14, 2016
   Google Scholar
• NittiVWAuerbachSMartinNCalhounALeeMHerschornSResults of a randomized phase III trial of mirabegron in patients with overactive bladderJ Urol201318941388139523079373
   PubMed Web of Science ®Google Scholar
• HaddadAJabbourMBulbulMPhosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: a comprehensive reviewArab J Urol201513315516126413339
   PubMed Web of Science ®Google Scholar
• GacciMCoronaGSalviMA systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasiaEur Urol2012615994100322405510
   PubMed Web of Science ®Google Scholar
• LythgoeCMcVaryKTThe use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasiaCurr Urol Rep201314658559424136683
   PubMed Web of Science ®Google Scholar
• GratzkeCHennenbergMStiefCPharmacology of the lower urinary tractIndian Journal of Urology201430218118824744518
   PubMedGoogle Scholar
• WangX-HWangXZhangX-HLiSLiuTShiM-JSystematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPHAsian Journal of Andrology20151761022103225994648
   PubMed Web of Science ®Google Scholar
• RoehrbornCGOyarzabal PerezIRoosEPMEfficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®)) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study resultsBJU Int2015116345045925565364
   PubMed Web of Science ®Google Scholar
• NickelJCRoehrbornCGO’LearyMPBostwickDGSomervilleMCRittmasterRSThe relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trialEur Urol20085461379138418036719
   PubMed Web of Science ®Google Scholar
• FüllhaseCHakenbergONew concepts for the treatment of male lower urinary tract symptomsCurr Opin Urol2015251192625393272
   PubMed Web of Science ®Google Scholar
• SchröderAColliEMaggiMAnderssonK-EEffects of a vitamin D3 analogue in a rat model of bladder outlet obstructionBJU International200698363764216925765
   PubMed Web of Science ®Google Scholar
• StrengTAnderssonK-EHedlundPEffects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstructionBJU International20121102bE125E13122288904
   PubMed Web of Science ®Google Scholar
• TiwariAElocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertilityIDrugs200912638139319517319
   PubMed Web of Science ®Google Scholar
• DigesuGAVerdiECardozoLOlivieriLKhullarVColliEPhase IIB, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine effects of elocalcitol in women with overactive bladder and idiopathic detrusor overactivityUrology2012801485422626580
   PubMed Web of Science ®Google Scholar
• FreemanRMAdekanmiOWaterfieldMRWaterfieldAEWrightDZajicekJThe effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)Int Urogynecol J2006176636641
   PubMed Web of Science ®Google Scholar
• BradyCMDasGuptaRDaltonCWisemanOJBerkleyKJFowlerCJAn open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosisMult Scler200410442543315327041
   PubMed Web of Science ®Google Scholar
• LeporHThe role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasiaRev Urol20068418318917192797
   PubMedGoogle Scholar
• DebruyneFTzvetkovMAltaracSGeavletePADose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasiaUrology201076492793320932411
   PubMed Web of Science ®Google Scholar
• DalyDMCollinsVMChappleCRGrundyDThe afferent system and its role in lower urinary tract dysfunctionCurr Opin Urol201121426827421537194
   PubMed Web of Science ®Google Scholar
• FrankenJUvinPDe RidderDVoetsTTRP channels in lower urinary tract dysfunctionBr J Pharmacol2014171102537255124895732
   PubMed Web of Science ®Google Scholar
• BurnstockGPurinergic signalling in the urinary tract in health and diseasePurinergic Signal201410110315524265069
   PubMed Web of Science ®Google Scholar
• GratzkeCBachmannADescazeaudAEAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstructionEur Urol20156761099110925613154
   PubMed Web of Science ®Google Scholar
• KirbyRSThe natural history of benign prostatic hyperplasia: what have we learned in the last decade?Urology2000565 Suppl 13611074195
   PubMed Web of Science ®Google Scholar